Trials / Terminated
TerminatedNCT01348503
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
A Phase I Open-label Dose-escalation Study With Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Indiana University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the combination of Revlimid® (lenalidomide) and Nexavar® (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured with surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide | Escalating doses starting at 15 mg by mouth per day. |
| DRUG | Sorafenib | Fixed dose of 400 mg by mouth twice a day. |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2012-12-01
- Completion
- 2014-03-01
- First posted
- 2011-05-05
- Last updated
- 2015-08-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01348503. Inclusion in this directory is not an endorsement.